40,716 results match your criteria Glioblastoma Multiforme


Radiochemical and biological properties of peptides designed to interact with EGF receptor: Relevance for glioblastoma.

Nucl Med Biol 2020 Jul 3;88-89:14-23. Epub 2020 Jul 3.

Department of Physiological Sciences, Santa Casa de Sao Paulo School of Medical Sciences, 01221-020 Sao Paulo, SP, Brazil. Electronic address:

Radiolabeled peptides with high specificity to receptors expressed on tumor cells hold a great promise as diagnostic and therapeutic tracers. The main objective of this study was to evaluate the radiochemical and biological properties of two [I]I-peptides, as well as their interaction with the epidermal growth factor receptor (EGFR), overexpressed in a wide variety of tumors, including glioblastoma. The EEEEYFELV peptide and its analogue DEDEYFELV, both designed to interact with EGFR, were chemically synthesized, purified and radiolabeled with iodine-131 ([I]NaI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nucmedbio.2020.07.001DOI Listing

Preclinical studies of a novel snake venom-derived recombinant disintegrin with antitumor activity: A review.

Biochem Pharmacol 2020 Jul 11:114149. Epub 2020 Jul 11.

Department of Biochemistry and Molecular Medicine, KSOM, USC, Los Angeles, CA 90089, USA. Electronic address:

Snake venoms consist of a complex mixture of many bioactive molecules. Among them are disintegrins, which are peptides without enzymatic activity, but with high binding affinity for integrins, transmembrane receptors that function to connect cells with components of the extracellular matrix. Integrin-mediated cell attachment is critical for cell migration and dissemination, as well as for signal transduction pathways involved in cell growth. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2020.114149DOI Listing

Glioblastoma multiforme: Metabolic differences to peritumoral tissue and IDH-mutated gliomas revealed by mass spectrometry imaging.

Neuropathology 2020 Jul 13. Epub 2020 Jul 13.

Proteome and Metabolome Research, Faculty of Biology & Center for Biotechnology, Bielefeld University, Bielefeld, Germany.

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor. High infiltration rates and poor therapy responses make it the deadliest glioma. The tumor metabolism is known to differ from normal one and is influenced through various factors which can lead to longer survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/neup.12671DOI Listing

Deep learning for glioblastoma segmentation using preoperative magnetic resonance imaging identifies volumetric features associated with survival.

Acta Neurochir (Wien) 2020 Jul 13. Epub 2020 Jul 13.

Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Level 3 A Block Box 165, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.

Background: Measurement of volumetric features is challenging in glioblastoma. We investigate whether volumetric features derived from preoperative MRI using a convolutional neural network-assisted segmentation is correlated with survival.

Methods: Preoperative MRI of 120 patients were scored using Visually Accessible Rembrandt Images (VASARI) features. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00701-020-04483-7DOI Listing

CDC6 is up-regulated and a poor prognostic signature in glioblastoma multiforme.

Clin Transl Oncol 2020 Jul 13. Epub 2020 Jul 13.

Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University and Institute of Brain and Brain-Inspired Science, Shandong University, Jinan, 250012, Shandong, China.

Purpose: Glioblastoma multiforme (GBM) represents the most common and the most malignant type of brain tumor. Cell division cycle 6 (CDC6), a gene associated with DNA replication initiation, has been proven to be associated with the prognosis of multiple tumors. In this study, we aim to explore the association between CDC6 expression and GBM carcinogenesis and prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12094-020-02449-wDOI Listing

A Molecular Signature associated with prolonged survival in Glioblastoma patients treated with Regorafenib.

Neuro Oncol 2020 Jul 14. Epub 2020 Jul 14.

Department of Neurosciences, Biomedicine and Movement, University of Verona, Verona.

Background: Patients with glioblastoma (GBM) have a dramatically poor prognosis. The recent REGOMA trial suggested an overall survival benefit of regorafenib in recurrent GBM patients. Considering the extreme genetic heterogeneity of GBMs, we aimed to identify molecular biomarkers predictive of differential response to the drug. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noaa156DOI Listing

Prevalence of Malignancy Among Urban Black Rheumatoid Arthritis Patients.

Int J Clin Res Trials 2020 25;5(1). Epub 2020 Apr 25.

Department of Medicine, Division of Pulmonary and Critical Care State, SUNY Downstate Medical Center/Health and Hospitals Kings County, Brooklyn, NY 11203, USA.

Background: Rheumatoid arthritis (RA) patients have an increased risk of malignancy with postulated risk factors that include chronic inflammation, smoking and the use of immunosuppressants have been postulated as drivers of higher malignancies rates. Our study aimed to describe the prevalence and type of malignancies encountered in an urban, predominantly Black RA patient population.

Methods: Cross sectional analysis of 1142 patients with RA diagnosis by ICD-codes of which 501 cases met the inclusion criteria for the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15344/2456-8007/2020/145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357963PMC

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.

ESMO Open 2020 Jul;5(4)

Medical Oncology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.

Background: Most glioblastoma tumours exhibit intrinsic phosphatidylinositol 3-kinase (PI3K) pathway activation. Preclinical in vitro and in vivo models suggest that buparlisib (an oral pan-PI3K inhibitor) can have an effect on glioblastoma directly and by enhancing the activity of radiation and of temozolomide.

Methods: This was a phase I, two-stage, multicentre, open-label, dose-escalation study of buparlisib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2020-000673DOI Listing

Manuscript prepared for submission to Therapeutic Advances in Medical Oncology Glioblastoma and bevacizumab in elderly patients: Monocentric study.

J Oncol Pharm Pract 2020 Jul 13:1078155220940396. Epub 2020 Jul 13.

AP-HP (Assistance publique Hôpitaux de Paris), Beaujon Hospital, Oncology Unit, France.

Purpose: A retrospective monocentric comparison of progression-free survival, overall survival, clinical benefit and tolerability between elderly (age>70) and non-elderly (age ≤ 70) patients receiving bevacizumab for recurrent glioblastoma.

Methods: We analyzed 47 patients with recurrent glioblastoma receiving bevacizumab (10 mg/kg every 14 days) between January 2011 and January 2014. Bevacizumab was introduced for all patients at recurrence after a first-line treatment by temozolomide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155220940396DOI Listing

Novel bexarotene derivatives: Synthesis and cytotoxicity evaluation for glioma cells in 2D and 3D in vitro models.

Eur J Pharmacol 2020 Jul 10:173346. Epub 2020 Jul 10.

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya Str. 16/10, 117997, Moscow, Russia.

Glioblastoma (GBM) is an aggressive and lethal form of brain cancer with a high invasion capacity and a lack of effective chemotherapeutics. Retinoid bexarotene (BXR) inhibits the neurospheroidal colony formation and migration of primary glioblastoma cells but has side effects. To enhance the BXR glioblastoma selectivity and cytotoxicity, we chemically modified it at the carboxyl group with either nitroethanolamine (NEA) with a NO-donating group (a well-known bioactivity enhancer; BXR-NEA) or a dopamine (DA) moiety (to represent the highly toxic for various tumor cells N-acyldopamine family; BXR-DA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2020.173346DOI Listing

Multi-scale segmentation in GBM treatment using diffusion tensor imaging.

Comput Biol Med 2020 May 22;123:103815. Epub 2020 May 22.

Department of Clinical Neuroscience, University of Cambridge, UK.

Glioblastoma (GBM) is the commonest primary malignant brain tumor in adults, and despite advances in multi-modality therapy, the outlook for patients has changed little in the last 10 years. Local recurrence is the predominant pattern of treatment failure, hence improved local therapies (surgery and radiotherapy) are needed to improve patient outcomes. Currently segmentation of GBM for surgery or radiotherapy (RT) planning is labor intensive, especially for high-dimensional MR imaging methods that may provide more sensitive indicators of tumor phenotype. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.compbiomed.2020.103815DOI Listing

Identification of Mir-9 in Glioma Diagnosis and Prognosis.

Clin Lab 2020 Jul;66(7)

Background: Mir-9 was recognized as a potential tumor suppressor gene or oncogene in varies of diseases; however, its roles in glioma have not been investigated. Our study was to identify the mRNA expression of mir-9 gene in glioma and correlate abnormal versions of microRNAs with clinicopathological features and investigate the impact of mir-9 in glioma prognosis.

Methods: Seventy-one glioma samples, which included 22 grade II, 24 grade III, and 25 glioblastoma tumors of previously untreated patients who underwent surgical excision at Qing Hai Province People's Hospital from 2011 to 2014, were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7754/Clin.Lab.2019.190914DOI Listing

Pulsed Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma.

Neuro Oncol 2020 Jul 13. Epub 2020 Jul 13.

Department of Radiation Oncology, Beaumont Health, Royal Oak, MI.

Background: Pulsed radiation therapy (PRT) has shown effective tumor control and superior normal-tissue sparing ability compared to standard radiotherapy (SRT) in pre-clinical models and retrospective clinical series. This is the first prospective trial to investigate PRT in the treatment of patients with newly diagnosed glioblastoma (GBM).

Methods: This is a single-arm, prospective study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noaa165DOI Listing

Human Cytomegalovirus (HCMV)-infected Astrocytoma Cells Impair the Function of HCMV-specific Cytotoxic T Cells.

J Korean Med Sci 2020 Jul 13;35(27):e218. Epub 2020 Jul 13.

Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Korea.

Background: Human cytomegalovirus (HCMV) infection in glioblastoma multiforme (GBM) is associated with a poor prognosis and may affect the pathogenesis of GBM. In this study, we investigated the role of HCMV-infected astrocytoma cells in impairing the activity of cytotoxic T lymphocytes (CTLs) specific to the HCMV protein.

Methods: CTLs specific to HCMV immediate early (IE)-1 were expanded from peripheral blood mononuclear cells of healthy donors by stimulating CD8+ T lymphocytes with U373MG cells (ATCC HTB-17: male) expressing HCMV IE-1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3346/jkms.2020.35.e218DOI Listing
July 2020
1.253 Impact Factor

Glioma cells survival depends both on fatty acid oxidation and on functional carnitine transport by SLC22A5.

J Neurochem 2020 Jul 12. Epub 2020 Jul 12.

Laboratory of Transport through Biomembranes, Nencki Institute of Experimental Biology of Polish Academy of Sciences, 3 Pasteur Street, 02-093, Warsaw, Poland.

Gliomas are the most common primary malignant brain tumor in adults, but current treatment for glioblastoma multiforme (GBM) is insufficient. Even though glucose is the primary energetic substrate of glioma cells, they are capable of using fatty acids to generate energy. Fatty acid oxidation (FAO) in mitochondria requires L-carnitine for the formation of acylcarnitines by carnitine palmitoylotransferase 1 (CPT1) and further transport of acyl carnitine esters to mitochondrial matrix. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jnc.15124DOI Listing

Update on glioma biotechnology.

Clin Neurol Neurosurg 2020 Jul 7;195:106075. Epub 2020 Jul 7.

Department of Neurosurgery, Lenox Hill Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA.

Neuro-oncological research is at the forefront of the rising cancer therapy market, as evidenced by its growing revenue and the multitude of clinical trials investigating innovative treatment approaches. The Feinstein Institute for Medical Research, in conjunction with the Department of Neurosurgery at Lenox Hill Hospital and the Zucker School of Medicine at Hofstra / Northwell, sponsored The Brain Tumor Biotech Summit in New York City in June 2019. The aim of the Summit was to provide a forum that encourages collaboration between cancer specialists, biotechnology and pharmaceutical industry leaders, and the investment community in order to promote innovation and advance emerging therapies for brain tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clineuro.2020.106075DOI Listing

Guiding Treatment Choices for Elderly Patients with Glioblastoma by a Comprehensive Geriatric Assessment.

Curr Oncol Rep 2020 Jul 10;22(9):93. Epub 2020 Jul 10.

Clinical Division of Palliative Care, Department of Internal Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

Purpose Of Review: The incidence of glioblastoma multiforme (GBM) increases with age; more than half of newly diagnosed patients are older than 65 years. Due to age-dependent decreasing organ functions, comorbidities, functional decline, and increasing risk of social isolation, not all patients are able to tolerate standard therapy of GBM with 6 weeks of radiochemotherapy.

Recent Findings: A set of alleviated therapies, e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-020-00951-6DOI Listing

A cytoskeleton regulator AVIL drives tumorigenesis in glioblastoma.

Nat Commun 2020 Jul 10;11(1):3457. Epub 2020 Jul 10.

Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA, 22908, USA.

Glioblastoma is a deadly cancer, with no effective therapies. Better understanding and identification of selective targets are urgently needed. We found that advillin (AVIL) is overexpressed in all the glioblastomas we tested including glioblastoma stem/initiating cells, but hardly detectable in non-neoplastic astrocytes, neural stem cells or normal brain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-020-17279-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351761PMC

Coding of Glioblastoma Progression and Therapy Resistance through Long Noncoding RNAs.

Cancers (Basel) 2020 Jul 8;12(7). Epub 2020 Jul 8.

Medical Centre for Molecular Biology, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia.

Glioblastoma is the most aggressive and lethal primary brain malignancy, with an average patient survival from diagnosis of 14 months. Glioblastoma also usually progresses as a more invasive phenotype after initial treatment. A major step forward in our understanding of the nature of glioblastoma was achieved with large-scale expression analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12071842DOI Listing

Mambalgin-2 Induces Cell Cycle Arrest and Apoptosis in Glioma Cells via Interaction with ASIC1a.

Cancers (Basel) 2020 Jul 8;12(7). Epub 2020 Jul 8.

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 119997 Moscow, Russia.

Gliomas are fast growing and highly invasive brain tumors, characterized by tumor microenvironment acidification that drives glioma cell growth and migration. Channels containing Acid-sensing Ion Channel 1a subunit (ASIC1a) mediate amiloride-sensitive cation influx in late stage glioma cells, but not in normal astrocytes. Thus, selective targeting of ASIC1a can be a perspective strategy for glioma treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12071837DOI Listing

Tumor-Targeting Peptides: The Functional Screen of Glioblastoma Homing Peptides to the Target Protein FABP3 (MDGI).

Cancers (Basel) 2020 Jul 8;12(7). Epub 2020 Jul 8.

Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland.

We recently identified the glioblastoma homing peptide CooP (CGLSGLGVA) using in vivo phage display screen. The mammary-derived growth inhibitor (MDGI/FABP3) was identified as its interacting partner. Here, we present an alanine scan of A-CooP to investigate the contribution of each amino acid residue to the binding to FABP3 by microscale thermophoresis (MST) and surface plasmon resonance (SPR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12071836DOI Listing

The Role of Liquid Biopsies in Detecting Molecular Tumor Biomarkers in Brain Cancer Patients.

Cancers (Basel) 2020 Jul 8;12(7). Epub 2020 Jul 8.

Centre for Circulating Tumour Cell Diagnostics and Research, Ingham Institute for Applied Medical Research, 1 Campbell St, Liverpool, NSW 2170, Australia.

Glioblastoma multiforme (GBM) is one of the most lethal primary central nervous system cancers with a median overall survival of only 12-15 months. The best documented treatment is surgical tumor debulking followed by chemoradiation and adjuvant chemotherapy with temozolomide, but treatment resistance and therefore tumor recurrence, is the usual outcome. Although advances in molecular subtyping suggests GBM can be classified into four subtypes, one concern about using the original histology for subsequent treatment decisions is that it only provides a static snapshot of heterogeneous tumors that may undergo longitudinal changes over time, especially under selective pressure of ongoing therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12071831DOI Listing

Comparative epidemiology of gliosarcoma and glioblastoma and the impact of Race on overall survival: A systematic literature review.

Clin Neurol Neurosurg 2020 Jun 29;195:106054. Epub 2020 Jun 29.

Case Western Reserve University School of Medicine, 10900 Euclid Ave, Cleveland, OH, USA; Department of Neurological Surgery, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Cleveland, OH, USA.

Objective: Gliosarcoma (GSM) is a rare subtype of glioblastoma (GBM) that accounts for approximately four percent of high-grade gliomas. There is scarce epidemiological data on patients with GSM as a distinct subgroup of GBM.

Methods: A systematic literature review was performed of peer-reviewed databases using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to evaluate the impact of race and ethnicity on survival in patients with GSM compared to patients with GBM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clineuro.2020.106054DOI Listing

Cell Lineage-Based Stratification for Glioblastoma.

Cancer Cell 2020 Jun 23. Epub 2020 Jun 23.

Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address:

Glioblastoma, the predominant adult malignant brain tumor, has been computationally classified into molecular subtypes whose functional relevance remains to be comprehensively established. Tumors from genetically engineered glioblastoma mouse models initiated by identical driver mutations in distinct cells of origin portray unique transcriptional profiles reflective of their respective lineage. Here, we identify corresponding transcriptional profiles in human glioblastoma and describe patient-derived xenografts with species-conserved subtype-discriminating functional properties. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2020.06.003DOI Listing

[Theranostics for glioblastoma with monoclonal antibodies to the epidermal growth factor receptor].

Zh Vopr Neirokhir Im N N Burdenko 2020 ;84(3):113-118

Burdenko Neurosurgical Center, Moscow, Russia.

A review is devoted to analysis of the prospects of theranostics for multiform glioblastoma with monoclonal antibodies to the epidermal growth factor receptor (EGFR). Treatment of various malignancies demonstrated high potential of the use of EGFR. However, in case of glioblastoma, the effectiveness of monoclonal antibodies to EGFR is constrained by the absence of informative criteria for assessing the effectiveness of diagnosis and treatment of disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17116/neiro202084031113DOI Listing
January 2020

[Glioblastomas in patients with medulloblastomas after combined treatment].

Zh Vopr Neirokhir Im N N Burdenko 2020 ;84(3):35-41

Sechenov University, Moscow, Russia.

Medulloblastoma (MB) is the most common brain malignancy in children occurring in the posterior cranial fossa. This tumor is characterized by high risk of metastasis along the CSF pathways. Significant progress in research of this tumor and appropriate treatment is associated with determining the various molecular categories of primary medulloblastomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17116/neiro20208403135DOI Listing
January 2020

Neurosurgical intraoperative ultrasonography using contrast enhanced superb microvascular imaging -vessel density and appearance time of the contrast agent.

Br J Neurosurg 2020 Jul 10:1-10. Epub 2020 Jul 10.

Department of Orthopedics, Edogawa Hospital, Tokyo, Japan.

Ultrasonography (US) provides real-time information on structures within the skull during neurosurgical operations. Superb microvascular imaging (SMI) is the latest imaging technique for detecting very low-velocity flow with minimal motion artifacts, and we have reported on this technique for intraoperative US monitoring. We combined SMI with administration of contrast agent to obtain detailed information during neurosurgical operations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/02688697.2020.1772958DOI Listing

Temozolomide-Doxorubicin Conjugate as a Double Intercalating Agent and Delivery by Apoferritin for Glioblastoma Chemotherapy.

ACS Appl Mater Interfaces 2020 Jul 10. Epub 2020 Jul 10.

We designed a conjugated compound by coupling temozolomide (TMZ) with doxorubicin (DOX) via an acylhydrazone linkage as a potential prodrug used for glioblastoma multiforme (GBM) treatment. Viscosity and spectroscopic studies revealed that the drug conjugate could act as a non-classical double intercalating agent. Although free TMZ is an inefficient DNA binder in comparison to DOX, the TMZ moiety interacted with DNA as an induced intercalator, arising from the synergistic effect of DOX moiety that mediated conformational changes of DNA helix. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsami.0c08531DOI Listing

Effect of Cumulative Dexamethasone Dose during Concomitant Chemoradiation on Lymphopenia in Patients with Newly Diagnosed Glioblastoma.

Brain Tumor Res Treat 2020 Jun 29. Epub 2020 Jun 29.

Department of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Background: Lymphopenia frequently occurs after concomitant chemoradiation (CCRT) in patients with glioblastoma (GBM) and is associated with worse overall survival (OS). A few studies have tried to identify risk factors for lymphopenia; however, the results were not clear. We aimed to identify potential risk factors for lymphopenia, focusing on the use of dexamethasone to control cerebral edema in patients with GBM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14791/btrt.2020.8.e12DOI Listing

Low Fraction Size Re-irradiation for Large Volume Recurrence of Glial Tumours.

Pathol Oncol Res 2020 Jul 9. Epub 2020 Jul 9.

Department of Oncotherapy, University of Szeged, Korányi fasor 12, Szeged, H-6720, Hungary.

The aim of the present study was to evaluate the efficacy of re-irradiation (re-RT) in patients with advanced local relapses of glial tumours and to define the factors influencing the result of the hyper-fractionated external beam therapy on progression after primary management. We have analysed the data of 55 patients with brain tumours (GBM: 28) on progression, who were re-irradiated between January 2007 and December 2018. The mean volume of the recurrent tumour was 118 cm, and the mean planning target volume (PTV) was 316 cm, to which 32 Gy was delivered in 20 fractions at least 7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12253-020-00868-2DOI Listing

The Multipotential of Leucine-Rich α-2 Glycoprotein 1 as a Clinicopathological Biomarker of Glioblastoma.

J Neuropathol Exp Neurol 2020 Jul 10. Epub 2020 Jul 10.

Department of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Kanazawa (TF, MN), Japan.

Leucine-rich α-2 glycoprotein 1 (LRG1) is a diagnostic marker candidate for glioblastoma. Although LRG1 has been associated with angiogenesis, it has been suggested that its biomarker role differs depending on the type of tumor. In this study, a clinicopathological examination of LRG1's role as a biomarker for glioblastoma was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnen/nlaa058DOI Listing

Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts.

J Neuropathol Exp Neurol 2020 Jul 10. Epub 2020 Jul 10.

From the Department of Pathology, State University of New York, Upstate Medical University, Syracuse, New York (KG, KM, RJC, TER).

IDH-wildtype glioblastoma is a relatively common malignant brain tumor in adults. These patients generally have dismal prognoses, although outliers with long survival have been noted in the literature. Recently, it has been reported that many histologically lower-grade IDH-wildtype astrocytomas have a similar clinical outcome to grade IV tumors, suggesting they may represent early or undersampled glioblastomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnen/nlaa059DOI Listing

Periostin Is Expressed by Pericytes and Is Crucial for Angiogenesis in Glioma.

J Neuropathol Exp Neurol 2020 Jul 10. Epub 2020 Jul 10.

From the Laboratory for Tumor Immunopathology, Department of Pathology (KH, CZ, BK, DZ, MvdW, TPPvdB, JD, JMK, DAM).

The expression of the matricellular protein periostin has been associated with glioma progression. In previous work we found an association of periostin with glioma angiogenesis. Here, we screen gliomas for POSTN expression and identify the cells that express periostin in human gliomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnen/nlaa067DOI Listing

Dissecting and rebuilding the glioblastoma microenvironment with engineered materials.

Nat Rev Mater 2019 Oct 16;4(10):651-668. Epub 2019 Aug 16.

University of California, Berkeley - University of California, San Francisco Graduate Program in Bioengineering, Berkeley, California, 94720, USA.

Glioblastoma (GBM) is the most aggressive and common form of primary brain cancer. Several decades of research have provided great insight into GBM progression; however, the prognosis remains poor with a median patient survival time of ~ 15 months. The tumour microenvironment (TME) of GBM plays a crucial role in mediating tumour progression and thus is being explored as a therapeutic target. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41578-019-0135-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347297PMC
October 2019

Multivariate analysis reveals differentially expressed genes among distinct subtypes of diffuse astrocytic gliomas: diagnostic implications.

Sci Rep 2020 Jul 9;10(1):11270. Epub 2020 Jul 9.

Instituto de Investigación biomédica de Salamanca, IBSAL- University Hospital of Salamanca, Salamanca, Spain.

Diagnosis and classification of gliomas mostly relies on histopathology and a few genetic markers. Here we interrogated microarray gene expression profiles (GEP) of 268 diffuse astrocytic gliomas-33 diffuse astrocytomas (DA), 52 anaplastic astrocytomas (AA) and 183 primary glioblastoma (GBM)-based on multivariate analysis, to identify discriminatory GEP that might support precise histopathological tumor stratification, particularly among inconclusive cases with II-III grade diagnosed, which have different prognosis and treatment strategies. Microarrays based GEP was analyzed on 155 diffuse astrocytic gliomas (discovery cohort) and validated in another 113 tumors (validation set) via sequential univariate analysis (pairwise comparison) for discriminatory gene selection, followed by nonnegative matrix factorization and canonical biplot for identification of discriminatory GEP among the distinct histological tumor subtypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-67743-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347847PMC

Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles.

Sci Rep 2020 Jul 9;10(1):11292. Epub 2020 Jul 9.

Department of Biomedical Engineering, University of Manitoba, Winnipeg, MB, Canada.

Although doxorubicin (DOX) is an effective anti-cancer drug with cytotoxicity in a variety of different tumors, its effectiveness in treating glioblastoma multiforme (GBM) is constrained by insufficient penetration across the blood-brain barrier (BBB). In this study, biocompatible magnetic iron oxide nanoparticles (IONPs) stabilized with trimethoxysilylpropyl-ethylenediamine triacetic acid (EDT) were developed as a carrier of DOX for GBM chemotherapy. The DOX-loaded EDT-IONPs (DOX-EDT-IONPs) released DOX within 4 days with the capability of an accelerated release in acidic microenvironments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-68017-yDOI Listing

neurotoxin A induces apoptosis and mitochondrial oxidative stress via activation of TRPM2 channel signaling pathway in neuroblastoma and glioblastoma tumor cells.

J Recept Signal Transduct Res 2020 Jul 9:1-13. Epub 2020 Jul 9.

Neuroscience Research Center, Suleyman Demirel University, Isparta, Turkey.

Background: The neurotoxin A (BTX) is a polypeptide produced by the bacterium . In addition to the therapeutic actions of BTX against pain and neuromuscular disorders, it is acted as anticancerogenic effect through excessive mitochondria reactive oxygen species (ROS) production, apoptosis, and caspase activations. The TRPM2 cation channel is activated by ROS and ADP-ribose and it is inhibited by 2-aminoethyl diphenylborinate (2-APB) and N-(p-amylcinnamoyl) anthranilic acid (ACA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10799893.2020.1781174DOI Listing

Sustained inhibition of PARP-1 activity delays glioblastoma recurrence by enhancing radiation-induced senescence.

Cancer Lett 2020 Jul 6. Epub 2020 Jul 6.

Shilpee Dutt Laboratory, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, India; Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai, 400085, India. Electronic address:

Glioblastoma (GBM) is the most common primary brain tumor and is highly aggressive with a median survival of 15 months. We have previously shown that residual cells of GBM form multinucleated giant cells (MNGCs) showing a senescent phenotype, but eventually escape from therapy induced senescence (TIS), resulting in GBM recurrence. Here we demonstrate the role of PARP-1 in TIS and its recovery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2020.06.023DOI Listing

An Antihuman Epidermal Growth Factor Receptor 2 Monoclonal Antibody (HMab-19) Exerts Antitumor Activity in Glioblastoma Xenograft Models.

Monoclon Antib Immunodiagn Immunother 2020 Jul 9. Epub 2020 Jul 9.

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.

Overexpression of human epidermal growth factor receptor 2 (HER2) has been reported in glioblastoma as well as breast, gastric, lung, colorectal, and pancreatic cancers. Its expression is associated with poor clinical outcomes. Anti-HER2 antibodies have provided significant survival benefits to patients with HER2-overexpressing breast and gastric cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/mab.2020.0013DOI Listing

Pulsed and Discontinuous Electromagnetic Field Exposure Decreases Temozolomide Resistance in Glioblastoma by Modulating the Expression of O-Methylguanine-DNA Methyltransferase, Cyclin-D1, and p53.

Cancer Biother Radiopharm 2020 Jul 9. Epub 2020 Jul 9.

Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.

Glioblastoma is a malignant and very aggressive brain tumor with a poor prognosis. Despite having chemotherapy concomitant with surgery and/or radiation therapy, the median survival of glioblastoma-affected people is less than 1 year. Temozolomide (TMZ) is a chemotherapy drug used today as the first line of glioblastoma treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/cbr.2020.3851DOI Listing

Genome-wide analysis of high-risk primary brain cancer pedigrees identifies PDXDC1 as a candidate brain cancer predisposition gene.

Neuro Oncol 2020 Jul 9. Epub 2020 Jul 9.

Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel.

Background: There is evidence for an inherited contribution to primary brain cancer. Linkage analysis of high-risk brain cancer pedigrees has identified candidate regions of interest in which brain cancer predisposition genes are likely to reside.

Methods/data: Genome-wide linkage analysis was performed in a unique set of 11 informative, extended, high-risk primary brain cancer pedigrees identified in a population genealogy database, which include from 2 to 6 sampled, related primary brain cancer cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noaa161DOI Listing

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential.

Hum Vaccin Immunother 2020 Jul 9:1-8. Epub 2020 Jul 9.

Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, China.

Immune checkpoint inhibitors (CIs) have changed the landscape of tumor immunotherapy. Glioblastoma (GBM) remains the most common primary malignant brain tumor in adults and has a very poor prognosis. Due to the high invasiveness and aggressiveness of GBM, there is considerable interest in programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/21645515.2020.1782692DOI Listing

Investigation of human cytomegalovirus and human papillomavirus in glioma.

Cancer Invest 2020 Jul 9:1-31. Epub 2020 Jul 9.

Higher Institute of Biotechnology, Monastir University, Monastir, Tunisia.

The study investigated the human cytomegalovirus (HCMV) and human papillomavirus (HPV) in gliomas. A retrospective study was conducted on 112 samples. HCMV was investigated by PCR, hybridization (ISH) and immunohistochemistry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/07357907.2020.1793352DOI Listing

Cognitive impairment three months after surgery is an independent predictor of survival time in glioblastoma patients.

J Neurooncol 2020 Jul 8. Epub 2020 Jul 8.

Department of Cognitive Neuropsychology, Tilburg University, Warandelaan 2, 5037 AB, Tilburg, The Netherlands.

Purpose: Cognitive functioning is increasingly investigated for its prognostic value in glioblastoma (GBM) patients, but the association of cognitive status during early adjuvant treatment with survival time is unclear. The aim of this study was to determine whether cognitive performance three months after surgical resection predicted survival time, while using a clinically intuitive time ratio (TR) statistic.

Methods: Newly diagnosed patients with GBM undergoing resection between November 2010 and February 2018 completed computerized cognitive assessment 3 months after surgery with the CNS Vital Signs battery (8 measures). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-020-03577-7DOI Listing

Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.

J Mol Neurosci 2020 Jul 8. Epub 2020 Jul 8.

Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, 110001, Liaoning, China.

Serine Incorporator 2 (SERINC2) is a transmembrane protein that incorporates serine into membrane lipids. The function of SERINC2 in tumors has been reported, but the role of SERINC2 in gliomas is not fully understood. RNA-sequencing data from The Cancer Genome Atlas (TCGA) (530 cases of low-grade glioma (LGG) and 173 cases of glioblastoma multiforme (GBM)) and microarray data from Gene Expression Omnibus (GEO) (Accession No. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12031-020-01620-wDOI Listing

Treatment and surgical factors associated with longer-term glioblastoma survival: a National Cancer Database study.

Neurooncol Adv 2020 Jul 4;2(Suppl 1):1-10. Epub 2020 Jun 4.

Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

Background: Insufficient data exist to characterize factors associated with longer-term survival of glioblastoma (GBM). A population-based analysis of GBM longer-term survivors (LTS) in the United States was conducted to investigate the association between treatment, demographic, surgical factors, and longer-term survival.

Methods: From the National Cancer Database, GBM patients were identified using ICD-O-3 histology codes 9440-9442/3, 2005-2015 and were divided into routine (≤3 years) and longer-term (>3 years) overall survival (OS) groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/noajnl/vdaa070DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332237PMC

Molecular profiling-based decision for targeted therapies in wild-type glioblastoma.

Neurooncol Adv 2020 Jan-Dec;2(1):vdz060. Epub 2020 Jan 22.

Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Background: Molecular profiling allows tumor classification as well as assessment of diagnostic, prognostic, and treatment-related molecular changes. Translation into clinical practice and relevance for patients has not been demonstrated yet.

Methods: We analyzed clinical and molecular data of isocitrate dehydrogenase wild-type glioblastoma patients with sufficient clinical follow-up from the Heidelberg Neuro-Oncology Center and with molecular analysis of tumor tissue that consisted of DNA methylation array data, genome-scale copy number variations, gene panel sequencing, and partly immunohistochemistry between October 2014 and April 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/noajnl/vdz060DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212885PMC
January 2020

TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors.

Neurooncol Adv 2020 Jan-Dec;2(1):vdz059. Epub 2020 Jan 24.

Department of Pathology (Neuropathology) and Instituto de Investigación i+12, Hospital Universitario 12 de Octubre, Madrid, Spain.

Background: Giant cell glioblastoma (gcGBM) is a rare morphological variant of IDH-wildtype (IDHwt) GBM that occurs in young adults and have a slightly better prognosis than "classic" IDHwt GBM.

Methods: We studied 36 GBMs, 14 with a histopathological diagnosis of gcGBM and 22 with a giant cell component. We analyzed the genetic profile of the most frequently mutated genes in gliomas and assessed the tumor mutation load (TML) by gene-targeted next-generation sequencing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/noajnl/vdz059DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212869PMC
January 2020